SCHEMBL1714756

SCHEMBL1714756

O=C(NOCCCCN(S)C(=O)Nc1ccccc1)c1ccccc1NCc1ccncc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.46
FLT1 P17948 7/20 0.46
KIT P10721 3/20 0.46
ABL1 P00519 2/20 0.46
CSF1R P07333 2/20 0.46
PDGFRB P09619 2/20 0.46
FLT4 P35916 2/20 0.46
EGFR P00533 1/20 0.46
BRAF P15056 1/20 0.42
IGF1R P08069 1/20 0.42
FGFR1 P11362 1/20 0.42
TEK Q02763 1/20 0.42
HTT P42858 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
POLB P06746 1/20 0.38
NAMPT P43490 1/20 0.37
CDC7 O00311 1/20 0.37
ROCK2 O75116 1/20 0.37
MAP4K4 O95819 1/20 0.37
GSK3B P49841 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1715407 0.94 KDR (0.48) KDRFLT1KITABL1CSF1R
SCHEMBL1714722 0.82 HTT (0.52) KDRFLT1KITABL1CSF1R
SCHEMBL1715201 0.81 HTT (0.53) KDRFLT1KITABL1CSF1R
SCHEMBL1714752 0.81 CA9 (0.50) KDRFLT1KITABL1CSF1R
SCHEMBL1715160 0.80 KDR (0.49) KDRFLT1KITABL1CSF1R
SCHEMBL1715054 0.79 KDR (0.48) KDRFLT1KITABL1CSF1R
SCHEMBL1715227 0.79 KDR (0.50) KDRFLT1KITABL1CSF1R
SCHEMBL1715148 0.79 HTT (0.55) KDRFLT1KITABL1CSF1R
SCHEMBL1715135 0.79 ALDH1A1 (0.48) KDRFLT1KITABL1CSF1R
SCHEMBL1714859 0.78 KDR (0.49) KDRFLT1KITABL1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP claimed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US claimed
JP-2007513098-A 2007-05-24 JP claimed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO claimed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 KDR 75/4885FLT1 19/4885KIT 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.